Skip to content

Insight, China's Pharmaceutical Industry

Fineline Insights, Pharma Clarity

  • Home
  • About US
  • Bioinsight
  • Policy Hub
  • Deals Book
  • Privacy Policy
  • Contact US

Header Toggle Sidebar

This is an example widget to show how the Header Toggle Sidebar looks by default. You can add custom widgets from the widgets in the admin.

Company Deals

RaysightMed Secures Nearly RMB 100 Million in Strategic Financing Led by State-Owned Capital – Accelerates Cardiovascular Diagnostics Scale-Up and AI Surgical Robotics Development

Fineline Cube Jul 1, 2026
Company Deals

Ribo Life Science Acquires Additional 25.93% Stake in Azemidite for RMB 70 Million – Strengthens siRNA Therapeutics Supply Chain

Fineline Cube Jul 1, 2026
Company Deals

METiS TechBio Signs Record $1.62B Global Licensing Deal for AI-Designed Tri-Specific TCE MTS-128 – Largest Preclinical TCE Out-Licensing by Chinese Pharma Company

Fineline Cube Jun 30, 2026
Company Deals

Eli Lilly Partners with Innovent Biologics on Verzenio CDK4/6 Inhibitor – Chinese Biotech Secures Exclusive Commercialization Rights in Mainland China

Fineline Cube Jun 30, 2026
Company Deals

Qyuns Therapeutics to Acquire Remaining 34% Stake in CMC Subsidiary Cellularforce for RMB 86M – Full Ownership Secures NDA Pathway for IL-17A and IL-4Rα Antibody Pipeline

Fineline Cube Jun 30, 2026
Policy / Regulatory

China’s CDE Unveils 108th Batch of Reference Preparations for Generic Drug Evaluation, Adds 28 New Drugs

Fineline Cube Jun 29, 2026
Company Drug

Hybio Pharma’s Generic Tirzepatide ANDA Accepted by FDA – First-to-File Challenger Targets $20B+ Dual GLP-1/GIP Agonist Franchise with Paragraph IV Certification

Fineline Cube Jul 1, 2026
Company Drug

Roche Receives FDA Priority Review for Enspryng in Thyroid Eye Disease – IL-6 Inhibitor Leverages Novel Recycling Technology for Second Indication

Fineline Cube Jul 1, 2026
Company Deals

Science Sun Pharma and Mabworks Biotech Sign Strategic Cooperation Pact

Fineline Cube Jul 11, 2022

Beijing Science Sun Pharmaceutical Co., Ltd (SHE: 300485) announced a strategic cooperation framework agreement with...

Company Deals

Hangzhou DAC Bio Partners with Janssen on ADC Development Deal

Fineline Cube Jul 11, 2022

China-based Hangzhou DAC Biotech Co., Ltd announced a licensing agreement with Janssen Pharmaceuticals Inc., a...

Policy / Regulatory

NHSA Sets 2022 Goals for Basic Medical Insurance Funding and Reforms

Fineline Cube Jul 8, 2022

The National Healthcare Security Administration (NHSA), Ministry of Finance (MOF), and State Taxation Administration (STA)...

Company Drug

Neurophth’s NR082 Gene Therapy Receives BTD for Leber Hereditary Optic Neuropathy

Fineline Cube Jul 8, 2022

China’s Center for Drug Evaluation (CDE) has awarded breakthrough therapy designation (BTD) to Wuhan Neurophth...

Company Drug

Biotheus Inc.’s PM1009 Bispecific Antibody Enters Clinical Trial Review for Solid Tumors

Fineline Cube Jul 8, 2022

China-based Biotheus Inc. announced that its clinical trial filing for PM1009, a bispecific antibody (BsAb)...

Company Deals

Rainmed Medical Makes IPO Debut on Hong Kong Exchange with Valuation Over USD 764M

Fineline Cube Jul 8, 2022

Suzhou Rainmed Medical Technology Co., Ltd, a China-based vascular intervention robot manufacturer, has completed its...

Company Deals

MicuRx Pharmaceuticals Approved for STAR Market IPO by CSRC

Fineline Cube Jul 8, 2022

The China Securities Regulatory Commission (CSRC) has approved the initial public offering (IPO) of Sino-US...

Company Drug

Innovent Biologics’ Pemazyre Becomes First FGFR2 Inhibitor Approved in China

Fineline Cube Jul 8, 2022

China-based Innovent Biologics Inc. (HKG: 1801) announced that the first prescription has been filled in...

Company Drug

Dizal Pharma’s DZD1516 Receives NMPA Green Light for HER2+ Breast Cancer Trial

Fineline Cube Jul 8, 2022

China-based Dizal Pharmaceutical Co., Ltd (SHA: 688192), spun out from AstraZeneca’s China drug discovery unit...

Company Deals

WuXi XDC Partners with AbTis to Advance ADC Development and Manufacturing

Fineline Cube Jul 8, 2022

WuXi XDC, a joint venture between Wuxi Biologics (HKG: 2269) and WuXi STA (SHA: 603259),...

Company Drug

GenScript Biotech’s Legend Biotech Terminates LB1901 CAR-T Phase I Trial

Fineline Cube Jul 8, 2022

Hong Kong-based GenScript Biotech Corporation (HKG: 1548) announced that its subsidiary Legend Biotech Corporation (NASDAQ:...

Company Deals Digital

ClouDr Group’s Hong Kong IPO Nets HKD 482 Million with Sanofi as Investor

Fineline Cube Jul 7, 2022

Hangzhou-based ClouDr Group Ltd (HKG: 9955), a one-stop chronic disease management and smart medical platform,...

Company Deals

Baifu Laser Raises RMB 100 Million in Series A Funding for Optoelectronic Equipment

Fineline Cube Jul 7, 2022

China-based Nanjing Baifu Laser Technology Co., Ltd reportedly raised close to RMB 100 million (USD...

Company Medical Device

Oriomics Launches XiaoWeiAn Multi-Tumor Early Screening Product

Fineline Cube Jul 7, 2022

Hangzhou Ao’rui Biological Technology Co., Ltd (Oriomics) announced the market launch of XiaoWeiAn, a multi-tumor...

Company Drug

Zhaoke Ophthalmology Enrolls First Patient in TAB014 Phase III Study for wAMD

Fineline Cube Jul 7, 2022

Lee’s Pharmaceutical Holdings Ltd’s (HKG: 0950) former subsidiary Zhaoke Ophthalmology Ltd (HKG: 6622) announced the...

Company Deals

GeneRulor Medical Technology Raises Funds for Gene Editing Diagnostics

Fineline Cube Jul 7, 2022

China-based gene editing specialist ZhuHai GeneRulor Medical Technology Co., Ltd. reportedly raised “tens of millions”...

Company Drug

Brii Biosciences Launches Anti-COVID-19 Antibody Cocktail in China

Fineline Cube Jul 7, 2022

China-based Brii Biosciences Ltd (HKG: 2137) announced the commercial launch in China of the anti-COVID-19...

Company Drug

Junshi Biosciences’ PD-1 Inhibitor Tuoyi Under FDA Review for NPC Treatment

Fineline Cube Jul 7, 2022

China-based Junshi Biosciences (HKG: 1877, SHA: 688180) announced that the Biologics License Application (BLA) for...

Company Deals

I-Mab and MorphoSys License Drugs to HIBio in Global Oncology Deal

Fineline Cube Jul 7, 2022

China-based I-Mab (NASDAQ: IMAB) detailed a licensing and equity investment deal between its German partner...

Company Deals

Adicon Holdings and Guardant Health Partner on Genomic Profiling in China

Fineline Cube Jul 7, 2022

China-based Adicon Holdings Limited announced a strategic partnership with U.S. firm Guardant Health, Inc. (NASDAQ:...

Posts pagination

1 … 675 676 677 … 689

Recent updates

  • Hybio Pharma’s Generic Tirzepatide ANDA Accepted by FDA – First-to-File Challenger Targets $20B+ Dual GLP-1/GIP Agonist Franchise with Paragraph IV Certification
  • Roche Receives FDA Priority Review for Enspryng in Thyroid Eye Disease – IL-6 Inhibitor Leverages Novel Recycling Technology for Second Indication
  • Huiyu Pharma Receives NMPA Clinical Trial Approval for HY-1016 Extended-Release Dienogest Injection – Novel Formulation Aims to Transform Endometriosis Treatment Adherence
  • RaysightMed Secures Nearly RMB 100 Million in Strategic Financing Led by State-Owned Capital – Accelerates Cardiovascular Diagnostics Scale-Up and AI Surgical Robotics Development
  • CSPC Innovation Launches Phase III Trial of SYS6010 ADC-PD-1 Combo in Resected NSCLC – Novel EGFR-Targeted Antibody-Drug Conjugate Enters Adjuvant Setting
Special Report 2025 Q1: U.S. Targets Chinese Pharma with 200% Tariffs—Will the Global Drug Market Collapse?

Category

  • Company
  • Deals
  • Digital
  • Drug
  • General/Other
  • Hospital
  • Legal / IP
  • Medical Device
  • Others
  • Policy / Regulatory
  • R&D

You Missed

Company Drug

Hybio Pharma’s Generic Tirzepatide ANDA Accepted by FDA – First-to-File Challenger Targets $20B+ Dual GLP-1/GIP Agonist Franchise with Paragraph IV Certification

Company Drug

Roche Receives FDA Priority Review for Enspryng in Thyroid Eye Disease – IL-6 Inhibitor Leverages Novel Recycling Technology for Second Indication

Company Drug

Huiyu Pharma Receives NMPA Clinical Trial Approval for HY-1016 Extended-Release Dienogest Injection – Novel Formulation Aims to Transform Endometriosis Treatment Adherence

Company Deals

RaysightMed Secures Nearly RMB 100 Million in Strategic Financing Led by State-Owned Capital – Accelerates Cardiovascular Diagnostics Scale-Up and AI Surgical Robotics Development

Insight, China's Pharmaceutical Industry

Fineline Insights, Pharma Clarity

Copyright © 2025 | Fineline Information & Technology | BlogData by Themeansar.